Evidence map›Paper›PMID 34581895›Full record

ArticleMedical oncology (Northwood, London, England)2021

Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling.

Erika Heninger, David Kosoff, Tamara S Rodems, Nan Sethakorn, Anupama Singh, Harshitha Gungurthi, Kristin N Carlson, Bing Yang, Cole Gilsdorf, Cheri A Pasch and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Medical oncology (Northwood, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Integrated analysis of the tumor microenvironment using a reconfigurable microfluidic cell culture platform.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Erika HeningerUniversity of Wisconsin Carbone Cancer Center, 1111 Highland Ave., Madison, USA.
David KosoffDepartment of Medicine, University of Wisconsin, Madison, 1111 Highland Ave., Madison, WI, 53705, USA.
Tamara S RodemsUniversity of Wisconsin Carbone Cancer Center, 1111 Highland Ave., Madison, USA.
Nan SethakornDepartment of Medicine, University of Wisconsin, Madison, 1111 Highland Ave., Madison, WI, 53705, USA.
Anupama SinghUniversity of Wisconsin Carbone Cancer Center, 1111 Highland Ave., Madison, USA.
Harshitha GungurthiUniversity of Wisconsin Carbone Cancer Center, 1111 Highland Ave., Madison, USA.
Kristin N CarlsonUniversity of Wisconsin Carbone Cancer Center, 1111 Highland Ave., Madison, USA.
Bing YangDepartment of Urology, 1111 Highland Ave., Madison, WI, 53705, USA.
Cole GilsdorfUniversity of Wisconsin Carbone Cancer Center, 1111 Highland Ave., Madison, USA.
Cheri A PaschUniversity of Wisconsin Carbone Cancer Center, 1111 Highland Ave., Madison, USA.
Dustin A DemingDepartment of Medicine, University of Wisconsin, Madison, 1111 Highland Ave., Madison, WI, 53705, USA.
Leigh EllisDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
David J BeebeDepartment of Pathology and Laboratory Medicine, 1111 Highland Ave., Madison, WI, 53705, USA.
David F JarrardDepartment of Urology, 1111 Highland Ave., Madison, WI, 53705, USA.
Joshua M LangUniversity of Wisconsin Carbone Cancer Center, 1111 Highland Ave., Madison, USA. jmlang@medicine.wisc.edu.ORCID http://orcid.org/0000-0002-0943-8872
University of Wisconsin Carbone Cancer Center · USUniversity of Wisconsin–Madison · USHighland Community College - Illinois · USCedars-Sinai Medical Center · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
RESEARCH TRAINING IN HEMATOLOGYT32HL007899 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI Jane Ellen Churpek · 1998 to 2026
$8.2M
Optical imaging to predict cell-level genetic heterogeneity and treatment sensitivity in colorectal cancerR37CA226526 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI DEMING, DUSTIN A · 2018 to 2024
$4.2M
NCI NIH HHS P30 CA014520NCI NIH HHS R37 CA226526NHLBI NIH HHS T32 HL007899Office of the Under Secretary of Defense W81XWH-16-1-0511Prostate Cancer Foundation 19CHAL12U.S. Department of Veterinary Affairs Advanced Fellowship in Women's Health T32 HL07899
6 · The paper itself

Abstract

Prostate Cancer (PC) is a disease with remarkable tumor heterogeneity that often manifests in significant intra-patient variability with regards to clinical outcomes and treatment response. Commonly available PC cell lines do not accurately reflect the complexity of this disease and there is critical need for development of new models to recapitulate the intricate hierarchy of tumor pathogenesis. In current study, we established ex vivo primary patient-derived cancer organoid (PDCO) cultures from prostatectomy specimens of patients with locally advanced PC. We then performed a comprehensive multi-parameter characterization of the cellular composition utilizing a novel approach for live-cell staining and direct imaging in the integrated microfluidic Stacks device. Using orthogonal flow cytometry analysis, we demonstrate that primary PDCOs maintain distinct subsets of epithelial cells throughout culture and that these cells conserve expression of androgen receptor (AR)-related elements. Furthermore, to confirm the tumor-origin of the PDCOs we have analyzed the expression of PC-associated epigenetic biomarkers including promoter methylation of the GSTP1, RASSF1 and APC and RARb genes by employing a novel microfluidic rare-event screening protocol. These results demonstrate that this ex vivo PDCO model recapitulates the complexity of the epithelial tumor microenvironment of multifocal PC using orthogonal analyses. Furthermore, we propose to leverage the Stacks microfluidic device as a high-throughput, translational platform to interrogate phenotypic and molecular endpoints with the capacity to incorporate a complex tumor microenvironment.

Indexed as

Cell Line, TumorHumansHyaluronan ReceptorsLab-On-A-Chip DevicesMaleOrganoidsProstatic NeoplasmsReceptors, AndrogenSignal TransductionTumor MicroenvironmentAR protein, humanCD44 protein, humanHyaluronan ReceptorsReceptors, AndrogenEpigenetic biomarkerMicrofluidicsPDCOPrimary cultureProstate cancer

Identifiers

PMID34581895
PMCPMC8478748
OpenAlexW3194426737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.